Krystal Biotech (NASDAQ:KRYS) PT Raised to $130.00 at Guggenheim

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target raised by Guggenheim from $101.00 to $130.00 in a research report released on Monday, The Fly reports.

KRYS has been the subject of several other research reports. Stifel Nicolaus initiated coverage on Krystal Biotech in a research report on Monday, April 17th. They issued a buy rating and a $102.00 price objective for the company. Bank of America upped their price target on Krystal Biotech from $105.00 to $118.00 in a research note on Sunday, May 21st. The Goldman Sachs Group raised Krystal Biotech from a neutral rating to a buy rating and increased their target price for the stock from $79.00 to $124.00 in a research note on Tuesday, February 28th. HC Wainwright upped their price target on Krystal Biotech from $119.00 to $139.00 in a report on Monday. Finally, William Blair reaffirmed an outperform rating on shares of Krystal Biotech in a report on Wednesday, March 22nd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $134.00.

Krystal Biotech Trading Down 1.0 %

Shares of NASDAQ KRYS opened at $117.39 on Monday. Krystal Biotech has a 12 month low of $49.17 and a 12 month high of $123.84. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -22.23 and a beta of 0.85. The business has a 50-day moving average of $86.67 and a 200-day moving average of $81.02.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last released its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.01. On average, analysts predict that Krystal Biotech will post -5.69 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $87.65, for a total value of $2,191,250.00. Following the transaction, the insider now owns 1,649,206 shares of the company’s stock, valued at $144,552,905.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $87.65, for a total transaction of $2,191,250.00. Following the completion of the sale, the insider now owns 1,649,206 shares in the company, valued at $144,552,905.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dino A. Rossi sold 40,000 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the sale, the director now owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Insiders have sold 193,428 shares of company stock valued at $17,965,513 over the last quarter. 17.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. bought a new stake in shares of Krystal Biotech in the 3rd quarter valued at approximately $52,000. Allspring Global Investments Holdings LLC raised its position in Krystal Biotech by 260.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 981 shares of the company’s stock valued at $68,000 after purchasing an additional 709 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Krystal Biotech by 51.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after acquiring an additional 346 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Krystal Biotech by 148.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 956 shares of the company’s stock valued at $77,000 after acquiring an additional 571 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Krystal Biotech in the 1st quarter valued at $104,000. Hedge funds and other institutional investors own 80.80% of the company’s stock.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.